Prognostic Significance of Epstein-Barr Virus Infection in Gastric Cancer: a Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Oct 27

PMID 26498209

Citations 33

Authors

Xuechao Liu

Jianjun Liu

Haibo Qiu

Pengfei Kong

Shangxiang Chen

Wei Li

Youqing Zhan

Yuanfang Li

Yingbo Chen

Zhiwei Zhou

Dazhi Xu

Xiaowei Sun

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic significance of Epstein-Barr virus (EBV) infection in gastric cancer (GC) remains unclear. Recently, a number of studies have investigated the association between EBV infection and the prognosis of GC with controversial results. We therefore conducted a meta-analysis to assess its prognostic significance.

Methods: PubMed and EMBASE were searched for studies up to October 1, 2014. We investigated the association between EBV infection with survival in patients with GC. The pooled hazard ratio (HR) and its 95% confidence interval (CI) were calculated to evaluate risk.

Results: A final analysis of 8,336 patients with GC from 24 studies was performed. Our analysis results indicated that the pooled HR was 0.67 (95% CI: 0.55-0.79; Z = 11.18, P < 0.001). Subgroup analyses stratified by region revealed that the protective role of EBV infection only remained in the Asian population (HR: 0.62, 95% CI: 0.48-0.75; P < 0.001). When stratified by study quality and statistical methodology, the protective role could also be identified in high quality studies (HR: 0.67, 95% CI: 0.55-0.79) and in univariate analysis studies (HR: 0.62, 95% CI: 0.50-0.74). There was no evidence of significant heterogeneity and publication bias.

Conclusions: The presence of EBV has a favorable impact on GC patient's survival, especially in an Asian population. Future updated studies, especially large-scale randomized controlled studies stratified by region, are warranted as validation studies.

Citing Articles

The landscape of 142 Epstein-Barr viral whole genomes in gastric cancer.

Kojima Y, Hamada M, Naruse A, Goto K, Khine H, Arai H J Gastroenterol. 2024; 60(1):55-65.

PMID: 39572460 DOI: 10.1007/s00535-024-02170-3.

Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.

Kim E, Chae H, Park Y, Ryu M, Kim H, Shin J Gastric Cancer. 2023; 27(1):146-154.

PMID: 38006567 DOI: 10.1007/s10120-023-01445-7.

Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study).

Alberti A, Stocker G, Lordick F, Hacker U, Kobitzsch B, Haffner I Front Oncol. 2023; 13:1276138.

PMID: 37941551 PMC: 10629611. DOI: 10.3389/fonc.2023.1276138.

Pathogenesis and therapeutic implications of EBV-associated epithelial cancers.

Low Y, Loh C, Peh D, Chu A, Han S, Toh H Front Oncol. 2023; 13:1202117.

PMID: 37901329 PMC: 10600384. DOI: 10.3389/fonc.2023.1202117.

Prognostic Implication of EBV Infection in Gastric Carcinomas: A Systematic Review and Meta-Analysis.

Pyo J, Kim N, Kang D Medicina (Kaunas). 2023; 59(5).

PMID: 37241066 PMC: 10221611. DOI: 10.3390/medicina59050834.

References

Chow W, Swanson C, Lissowska J, Groves F, Sobin L, Nasierowska-Guttmejer A . Risk of stomach cancer in relation to consumption of cigarettes, alcohol, tea and coffee in Warsaw, Poland. Int J Cancer. 1999; 81(6):871-6. DOI: 10.1002/(sici)1097-0215(19990611)81:6<871::aid-ijc6>3.0.co;2-#. View

Moher D, Liberati A, Tetzlaff J, Altman D . Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther. 2009; 89(9):873-80. View

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M . Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014; 20(38):13842-62. PMC: 4194567. DOI: 10.3748/wjg.v20.i38.13842. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Huang S, Ng K, Chen K, Hsu J, Liu K, Yeh T . Prognostic factors in Epstein-Barr virus-associated stage I-III gastric carcinoma: implications for a unique type of carcinogenesis. Oncol Rep. 2014; 32(2):530-8. DOI: 10.3892/or.2014.3234. View

Kijima Y, Ishigami S, Hokita S, Koriyama C, Akiba S, Eizuru Y . The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett. 2003; 200(1):33-40. DOI: 10.1016/s0304-3835(03)00410-5. View

Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y . Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol. 2012; 18(45):6577-86. PMC: 3516204. DOI: 10.3748/wjg.v18.i45.6577. View

Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N . Spectrum of Epstein-Barr virus-related diseases: a pictorial review. Jpn J Radiol. 2009; 27(1):4-19. DOI: 10.1007/s11604-008-0291-2. View

van Beek J, Zur Hausen A, Kranenbarg E, Warring R, Bloemena E, Craanen M . A rapid and reliable enzyme immunoassay PCR-based screening method to identify EBV-carrying gastric carcinomas. Mod Pathol. 2002; 15(8):870-7. DOI: 10.1097/01.MP.0000024147.43288.B1. View

10.

Selves J, Bibeau F, Brousset P, Meggetto F, Mazerolles C, Voigt J . Epstein-Barr virus latent and replicative gene expression in gastric carcinoma. Histopathology. 1996; 28(2):121-7. DOI: 10.1046/j.1365-2559.1996.287333.x. View

11.

Yuen S, Chung L, Leung S, Luk I, Chan S, Ho J . In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol. 1994; 18(11):1158-63. DOI: 10.1097/00000478-199411000-00010. View

12.

Camargo M, Murphy G, Koriyama C, Pfeiffer R, Kim W, Herrera-Goepfert R . Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011; 105(1):38-43. PMC: 3137422. DOI: 10.1038/bjc.2011.215. View

13.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

14.

Camargo M, Kim W, Chiaravalli A, Kim K, Corvalan A, Matsuo K . Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2013; 63(2):236-43. PMC: 4384434. DOI: 10.1136/gutjnl-2013-304531. View

15.

Hamashima C . Current issues and future perspectives of gastric cancer screening. World J Gastroenterol. 2014; 20(38):13767-74. PMC: 4194560. DOI: 10.3748/wjg.v20.i38.13767. View

16.

Lee H, Chang M, Yang H, Lee B, Kim W . Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma. Clin Cancer Res. 2004; 10(5):1698-705. DOI: 10.1158/1078-0432.ccr-1122-3. View

17.

Corvalan A, Koriyama C, Akiba S, Eizuru Y, Backhouse C, Palma M . Epstein-Barr virus in gastric carcinoma is associated with location in the cardia and with a diffuse histology: a study in one area of Chile. Int J Cancer. 2001; 94(4):527-30. DOI: 10.1002/ijc.1510. View

18.

Koriyama C, Akiba S, Itoh T, Sueyoshi K, Minakami Y, Corvalan A . E-cadherin and beta-catenin expression in Epstein-Barr virus-associated gastric carcinoma and their prognostic significance. World J Gastroenterol. 2007; 13(29):3925-31. PMC: 4171163. DOI: 10.3748/wjg.v13.i29.3925. View

19.

Shibata D, Tokunaga M, Uemura Y, Sato E, Tanaka S, Weiss L . Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol. 1991; 139(3):469-74. PMC: 1886210. View

20.

Hui K, Cheung A, Choi C, Yeung P, Middeldorp J, Lung M . Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int J Cancer. 2015; 138(1):125-36. DOI: 10.1002/ijc.29698. View